SILO Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
0
-100.0%
18.0K
+0.0%
18.0K
+0.0%
18.0K
+0.0%
18.0K
Cost of Revenue
0
-100.0%
20.7K
-0.0%
20.7K
+0.0%
20.7K
+1317.9%
1.5K
Gross Profit
0
+100.0%
-2662
+0.0%
-2663
-0.0%
-2662
-116.1%
16.6K
Operating Expenses
928.9K
-41.6%
1.6M
+103.1%
783.9K
-31.8%
1.1M
-9.2%
1.3M
R&D
298.4K
-70.5%
1.0M
+231.1%
306.0K
-43.7%
543.6K
-24.2%
717.2K
SG&A
630.5K
+9.0%
578.7K
+44.2%
401.4K
-25.7%
540.3K
-1.4%
547.9K
Operating Income
-928949
+41.7%
-1594660
-102.7%
-786524
+31.7%
-1151466
+7.8%
-1248551
EBITDA
-931886
+41.5%
-1591723
-103.1%
-783587
+31.8%
-1148528
+8.2%
-1251643
Net Income
-832829
+49.4%
-1647117
-86.8%
-881530
+20.6%
-1110438
+7.8%
-1204293
EPS (Basic)
$-0.76
-533.3%
$-0.12
-140.0%
$-0.05
+58.3%
$-0.12
+95.8%
$-2.88
EPS (Diluted)
$-0.76
-533.3%
$-0.12
-140.0%
$-0.05
+58.3%
$-0.12
+95.8%
$-2.88
Shares (Diluted)
1.1M
-92.0%
13.7M
-28.9%
19.3M
+106.8%
9.3M
+2128.9%
418.6K
Silo Pharma (SILO) โ€” Financials